Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Gsk Plc (GSK.LN)

Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 53,189,314
  • Shares Outstanding, K 4,080,500
  • Annual Sales, $ 30,328 M
  • Annual Income, $ 4,928 M
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales 1.72
  • Price/Cash Flow 7.26
  • Price/Book 3.80
  • Price/Earnings ttm 21.47
  • Earnings Per Share ttm 0.61
  • Most Recent Earnings $-0.01 on 10/30/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.60 (4.60%)
  • Most Recent Dividend 0.150 on 11/14/24
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,282.500 +2.20%
on 11/15/24
1,464.000 -10.47%
on 10/22/24
-153.280 (-10.47%)
since 10/21/24
3-Month
1,282.500 +2.20%
on 11/15/24
1,678.680 -21.92%
on 09/09/24
-285.280 (-17.87%)
since 08/21/24
52-Week
1,282.500 +2.20%
on 11/15/24
1,823.500 -28.12%
on 05/16/24
-106.680 (-7.53%)
since 11/21/23
Free Barchart Webinars! Live educational sessions using site features to explore today's markets.

Most Recent Stories

More News
Nasdaq Times Square by Lucky Photographer via iStock
Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap Barchart - Wed Oct 30, 4:40AM CDT

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data...

PYPL : 85.06 (+0.38%)
KLAC : 616.59 (-0.04%)
GOOGL : 174.56 (-0.81%)
META : 569.30 (+0.67%)
AVGO : 165.56 (+1.42%)
RDDT : 141.18 (+3.60%)
F : 10.77 (+0.37%)
NQZ24 : 20,876.75 (+0.62%)
ABBV : 168.23 (+0.28%)
SNAP : 10.68 (+0.85%)
DASH : 172.20 (-2.26%)
GSK.LN : 1,309.000 (+0.69%)
Wall Street - New York Stock Exchange NYSE in Manhattan by 4kclips via Shutterstock
Stocks Muted Before the Open With U.S. Inflation Data in Focus Barchart - Thu Oct 10, 4:42AM CDT

December S&P 500 E-Mini futures (ESZ24) are down -0.15%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.23% this morning as investors refrained from making any big bets ahead of a key U.S....

PYPL : 85.06 (+0.38%)
GOOGL : 174.56 (-0.81%)
CVS : 56.89 (+0.11%)
TXG : 13.45 (+0.98%)
JPM : 242.37 (+0.66%)
NQZ24 : 20,876.75 (+0.62%)
NKE : 73.54 (+0.25%)
GSK.LN : 1,309.000 (+0.69%)
PFE : 24.85 (-0.36%)
NCLH : 26.19 (+0.58%)
WFC : 74.05 (+0.64%)
ALTM : 5.18 (-0.58%)
Wall Street - shutterstock_1321462400
Stocks Set to Open Higher as Rate Cut Bets Firm, U.S. Jobs Data in Focus Barchart - Mon Jun 3, 4:33AM CDT

June S&P 500 E-Mini futures (ESM24) are up +0.25%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.37% this morning as speculation over interest rate cuts by major central banks heightened appetite...

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
CZR : 37.73 (+0.37%)
ZS : 201.32 (+0.19%)
GPS : 24.55 (+4.38%)
MDB : 303.00 (+7.54%)
CRWD : 353.26 (+0.89%)
GTLB : 63.99 (+2.96%)
HPE : 21.35 (+0.80%)
BBWI : 30.50 (-0.03%)
LULU : 309.93 (+0.53%)
DLTR : 62.90 (-0.44%)
Moderna Investors Just Got Some Bullish News Motley Fool - Mon Jun 3, 3:50AM CDT

This news could be worth billions...

GSK.LN : 1,309.000 (+0.69%)
PFE : 24.85 (-0.36%)
MRNA : 36.35 (-1.60%)
Is This a Setback for Moderna? Motley Fool - Tue May 14, 5:35AM CDT

Moderna's shares slipped after the company announced the delay.

PFE : 24.85 (-0.36%)
GSK.LN : 1,309.000 (+0.69%)
MRNA : 36.35 (-1.60%)
Drug Patents
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition Associated Press - Tue Apr 30, 4:36PM CDT

The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic

AZN.LN : 10,014.000 (+0.45%)
AZN : 63.71 (+0.81%)
GSK.LN : 1,309.000 (+0.69%)
GSK : 33.39 (+0.12%)
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. Motley Fool - Tue Apr 9, 5:35AM CDT

These companies are close to launching new products that could supercharge revenue.

LLY : 753.00 (-0.05%)
PFE : 24.85 (-0.36%)
GSK.LN : 1,309.000 (+0.69%)
MRNA : 36.35 (-1.60%)
VRTX : 452.44 (+0.27%)
RSV Drug
Babies should get recently approved drug for RSV, CDC says Associated Press - Thu Aug 3, 2023

U.S. health officials are recommending that babies get a recently approved drug to protect them against a respiratory virus

PFE : 24.85 (-0.36%)
GSK.LN : 1,309.000 (+0.69%)
GSK : 33.39 (+0.12%)
AZN.LN : 10,014.000 (+0.45%)
AZN : 63.71 (+0.81%)
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Newswire.ca - Wed Jun 28, 2023

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...

BLU : 14.74 (unch)
GSK.LN : 1,309.000 (+0.69%)
GSK : 33.39 (+0.12%)
BLU.TO : 19.48 (-0.10%)
Author
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results MarketBeat - Mon May 8, 2023

Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug

SGEN : 228.74 (-0.07%)
AZN : 63.71 (+0.81%)
IMGN : 31.23 (unch)
GSK : 33.39 (+0.12%)
GSK.LN : 1,309.000 (+0.69%)
PFE : 24.85 (-0.36%)
More news for this symbol

Barchart Technical Opinion

Strong sell

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 1,317.333
2nd Resistance Point 1,313.667
1st Resistance Point 1,306.833
Last Price 1,309.000
1st Support Level 1,296.333
2nd Support Level 1,292.667
3rd Support Level 1,285.833

See More

52-Week High 1,823.500
Fibonacci 61.8% 1,616.838
Fibonacci 50% 1,553.000
Fibonacci 38.2% 1,489.162
Last Price 1,309.000
52-Week Low 1,282.500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot